-
Transient Ischemic Attack-Not So Transient After All! JAMA Neurol. (IF 20.4) Pub Date : 2025-02-10 Eric E Smith,Babak B Navi
-
Aligning Alzheimer Disease Biology With Care. JAMA Neurol. (IF 20.4) Pub Date : 2025-02-10 Fred B Ketchum,Nathaniel A Chin,Joshua D Grill
-
Cognitive Decline After First-Time Transient Ischemic Attack JAMA Neurol. (IF 20.4) Pub Date : 2025-02-10 Victor A. Del Bene, George Howard, Toby I. Gropen, Michael J. Lyerly, Virginia J. Howard, Russell P. Sawyer, Ronald M. Lazar
ImportancePrior research suggests reduced cognitive function after transient ischemic attack (TIA). Whether this is directly related to the TIA, a function of preexisting risk factors, or prior cognitive decline remains unclear.ObjectiveTo study if a single, diffusion-weighted image–negative, adjudicated TIA is associated with longitudinal declines in cognition, independent of preexisting risk factors
-
Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers JAMA Neurol. (IF 20.4) Pub Date : 2025-02-10 Lawren VandeVrede, Hanna Cho, Mark Sanderson-Cimino, Fattin Wekselman, Yann Cobigo, Maria Luisa Gorno-Tempini, Hilary W. Heuer, Joel H. Kramer, Argentina Lario Lago, Dana Leichter, Peter Ljubenkov, Bruce L. Miller, David C. Perry, Gil D. Rabinovici, Julio C. Rojas, Howard J. Rosen, Rowan Saloner, Adam Staffaroni, Gallen Triana-Baltzer, Salvatore Spina, William W. Seeley, Lea T. Grinberg, Hartmuth C
ImportanceBlood-based biomarkers for Alzheimer disease (AD) are clinically available, but their value is not well understood in syndromes typically associated with frontotemporal lobar degeneration syndromes (FTLD).ObjectiveTo investigate the clinical importance and detectability of AD in FTLD-related neurodegenerative syndromes using 3 plasma biomarkers, phosphorylated tau 217 (p-tau217), neurofilament
-
Central Retinal Artery Occlusion With Cilioretinal Artery Sparing After Semaglutide Injection JAMA Neurol. (IF 20.4) Pub Date : 2025-02-10 Julie M. Shabto, Jin Kyun Oh, Tarun Sharma
This case report highlights a temporal relationship between the use of a glucagon-like peptide-1 receptor (GLP-1) agonist and the occurrence of central retinal artery occlusion.
-
Ischemic Stroke Due to Compression of a Wandering Internal Carotid Artery by the Hyoid Bone. JAMA Neurol. (IF 20.4) Pub Date : 2025-02-03 François Bouille,Maxime De Malherbe,Fernando Pico
-
Risk of Attempted and Completed Suicide in Persons Diagnosed With Headache JAMA Neurol. (IF 20.4) Pub Date : 2025-02-03 Holly Elser, Dóra Körmendiné Farkas, Cecilia Hvitfeldt Fuglsang, Sissel Toft Sørensen, Henrik Toft Sørensen
ImportanceAlthough past research suggests an association between migraine and attempted suicide, there is limited research regarding risk of attempted and completed suicide across headache disorders.ObjectiveTo examine the risk of attempted and completed suicide associated with diagnosis of migraine, tension-type headache, posttraumatic headache, and trigeminal autonomic cephalalgia (TAC).Design, Setting
-
Research Priorities in Neuropalliative Care JAMA Neurol. (IF 20.4) Pub Date : 2025-02-03 Winnie K. Lau, Corey R. Fehnel, Zachary A. Macchi, Ambereen K. Mehta, Manon Auffret, Jori F. Bogetz, Jori E. Fleisher, Jerome J. Graber, Heather E. Leeper, Heena R. Manglani-Terranova, Susanne Muehlschlegel, Emily L. Mroz, Elizabeth J. Pedowitz, Usha Ramanathan, Max Sarmet, Nathan A. Shlobin, Leonard Sokol, Susan Allyson Weeks, Jiayun Xu, Helen Bundy Medsger, Claire J. Creutzfeldt, Ana-Maria Vranceanu
ImportanceThe integration of palliative care in neurology, or neuropalliative care, is an emerging area of practice focused on holistically improving quality of life and reducing the burden of suffering for people living with serious neurologic disease and their care partners. Major neurology and palliative care societies have recognized the need to advance primary and specialty palliative care services
-
Neuromodulation for Children With Hemiparesis and Perinatal Stroke JAMA Neurol. (IF 20.4) Pub Date : 2025-02-03 Alicia J. Hilderley, Mary Dunbar, John Andersen, Darcy Fehlings, Megan Metzler, Helen L. Carlson, Ephrem Zewdie, Jacquie Hodge, Kathleen O’Grady, Lisa Carsolio, Nomazulu Dlamini, Adrianna Giuffre, Lauran Cole, Hsing-Ching Kuo, Anna Bourgeois, Asha Hollis, Meghan Maiani, Patrick Ciechanski, Zeanna Jadavji, Brandon Craig, Dion Kelly, Joanna Keough, James Wrightson, Linda Fay, Lauren Switzer, Maya Pajevic
ImportanceCurrent upper-extremity therapies provide inconsistent outcomes for children with unilateral cerebral palsy. Noninvasive brain stimulation, specifically transcranial direct current stimulation, may enhance motor gains when combined with therapy.ObjectiveTo determine whether the addition of neurostimulation to upper-extremity therapy enhances motor function in children with perinatal stroke
-
Anticoagulation in ESUS-Back From the Dead? JAMA Neurol. (IF 20.4) Pub Date : 2025-01-27 Holly Elser,S Andrew Josephson
-
Cognitive Effects of MR-Guided Focused Ultrasound Thalamotomy-Time to Evaluation. JAMA Neurol. (IF 20.4) Pub Date : 2025-01-27 Mickael Aubignat,Olivier Godefroy
-
Cognitive Effects of MR-Guided Focused Ultrasound Thalamotomy-Time to Evaluation-Reply. JAMA Neurol. (IF 20.4) Pub Date : 2025-01-27 Michael G Kaplitt,Vibhor Krishna,Howard M Eisenberg
-
Predicting Individual Pain Sensitivity Using a Novel Cortical Biomarker Signature JAMA Neurol. (IF 20.4) Pub Date : 2025-01-27 Nahian S. Chowdhury, Chuan Bi, Andrew J. Furman, Alan K. I. Chiang, Patrick Skippen, Emily Si, Samantha K. Millard, Sarah M. Margerison, Darrah Spies, Michael L. Keaser, Joyce T. Da Silva, Shuo Chen, Siobhan M. Schabrun, David A. Seminowicz
ImportanceBiomarkers would greatly assist decision-making in the diagnosis, prevention, and treatment of chronic pain.ObjectiveTo undertake analytical validation of a sensorimotor cortical biomarker signature for pain consisting of 2 measures: sensorimotor peak alpha frequency (PAF) and corticomotor excitability (CME).Design, Setting, and ParticipantsThis cohort study at a single center (Neuroscience
-
Integrating N-of-1 Trials Into Learning Health Care Systems JAMA Neurol. (IF 20.4) Pub Date : 2025-01-27 Julia E. H. Brown, Winston Chiong, Nora Hutchinson
This Viewpoint explores how current ethical challenges of N-of-1 trials for serious neurological diseases could be addressed by integrating current approaches into learning healthcare systems.
-
Apixaban to Prevent Covert Infarcts After Cryptogenic Stroke in Patients With Atrial Cardiopathy JAMA Neurol. (IF 20.4) Pub Date : 2025-01-27 Maarten G. Lansberg, Max Wintermark, Hui Chen, George Howard, Christy Cassarly, Qi Pauls, Stephanie Kemp, Tashia L. Harris, Balaji Krishnaiah, Robert J. Stanton, Michael J. Lyerly, Benjamin R. Miller, Eric E. Smith, David L. Tirschwell, Kevin N. Sheth, Hooman Kamel, William T. Longstreth, Mitchell S. V. Elkind, Joseph P. Broderick, Ronald M. Lazar
ImportanceIn the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) randomized clinical trial, anticoagulation did not prevent recurrent stroke among patients with a recent cryptogenic stroke and atrial cardiopathy. It is unknown whether anticoagulation prevents covert infarcts in this population.ObjectiveTo test the use of apixaban vs aspirin for prevention
-
A 61-Year-Old Man With Weakness and Gait Dysfunction JAMA Neurol. (IF 20.4) Pub Date : 2025-01-21 Felipe J. S. Jones, Christyn Edmundson, Jennifer Orthmann-Murphy
A man aged 61 years presented with chronic progressive weakness and gait dysfunction over a 4-year period. He had Ashkenazi Jewish ancestry and a history of memory loss, inappropriate laughter, dysarthria, and hypertension. Examination revealed impaired recall, extremity spasticity, distal sensory loss, and normal cerebellar function, and imaging showed hyperintensities in the periventricular white
-
Autoimmune Inflammatory Astrocytopathies-Is the Spectrum Expanding? JAMA Neurol. (IF 20.4) Pub Date : 2025-01-21 Samuel J Pleasure,Ari J Green
-
Novel Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies JAMA Neurol. (IF 20.4) Pub Date : 2025-01-21 Dongshan Wan, Shufang Zhao, Chen Zhang, Fang Xu, Huizi Wang, Shaoxin Tao, Zhandong Qiu, Hao Jiang, Dawei Li, Fei Wang, Dong Li, Jiahao Chen, Yan Wang, Yao Yan, Yan Zhao, Xiaohan Gao, Bingxue Jin, Di Liu, Mengyao Zhang, Jingjing Feng, Shiyue Hou, Mingyang Wang, Teng Chen, Ming Lin, Jinming Han, Xinmei Wen, Wei Jiang, Liang Liu, Youming Long, Yinan Zhao, Jun-Ichi Kira, Zheng Liu, Guoliang Chai, Junwei
ImportanceAutoantibodies targeting astrocytes, such as those against glial fibrillary acidic protein (GFAP) or aquaporin protein 4, are crucial diagnostic markers for autoimmune astrocytopathy among central nervous system (CNS) autoimmune disorders. However, diagnosis remains challenging for patients lacking specific autoantibodies.ObjectiveTo characterize a syndrome of unknown meningoencephalomyelitis
-
Prourokinase vs Standard Care for Patients With Mild Ischemic Stroke: The PUMICE Randomized Clinical Trial. JAMA Neurol. (IF 20.4) Pub Date : 2025-01-21 Yunyun Xiong,Xia Meng,Aoming Jin,Bruce C V Campbell,Anding Xu,Qiang Dong,Yun Xu,Yuesong Pan,Yong Jiang,Siying Niu,Zhiliang Li,Xianbo Zhuang,Na Guo,Zhimei Yuan,Zhenyu Kong,Lixia Zong,Chunmiao Duan,Zhixin Cao,Liyuan Wang,Manjun Hao,Shuangzhe Wu,Xueyan Feng,Hao Li,Na Wu,Zixiao Li,Xingquan Zhao,Yongjun Wang,
Importance Trials have not demonstrated superiority of alteplase or tenecteplase vs standard care in patients with mild stroke and have raised safety concerns. Prourokinase is an alternative fibrinolytic that may have a favorable safety profile, and the benefit-risk profile of prourokinase in mild stroke is unknown. Objective To investigate the efficacy and safety of prourokinase in mild ischemic stroke
-
Reimagining Care and Research for Amyotrophic Lateral Sclerosis JAMA Neurol. (IF 20.4) Pub Date : 2025-01-21 Suma Babu, Joshua M. Sharfstein, Eva L. Feldman
This Viewpoint advocates for the expansion of clinical research in amyotrophic lateral sclerosis through the development of a well-organized network of centers and community-based clinics.
-
Errors in the Title, Short Title, and Additional Contributions. JAMA Neurol. (IF 20.4) Pub Date : 2025-01-13
-
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension. JAMA Neurol. (IF 20.4) Pub Date : 2025-01-13 David Adams,Jonas Wixner,Michael Polydefkis,John L Berk,Isabel M Conceição,Angela Dispenzieri,Amanda Peltier,Mitsuharu Ueda,Shaun Bender,Kelley Capocelli,Patrick Y Jay,Elena Yureneva,Laura Obici,
Importance There is a lack of long-term efficacy and safety data on hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) and on RNA interference (RNAi) therapeutics in general. This study presents the longest-term data to date on patisiran for hATTR-PN. Objective To present the long-term efficacy and safety of patisiran in adults with hATTR-PN. Design, Setting, and Participants This
-
An Imperative for Public Sharing of Adverse Events of Gene Therapy Trials. JAMA Neurol. (IF 20.4) Pub Date : 2025-01-13 Joshua L Bonkowsky,Deepa S Rajan,Florian Eichler
-
Longitudinal FDG-PET Metabolic Change Along the Lewy Body Continuum JAMA Neurol. (IF 20.4) Pub Date : 2025-01-13 Daniel Ferreira, Scott A. Przybelski, Timothy G. Lesnick, Patricia Diaz-Galvan, Christopher G. Schwarz, Melissa M. Murray, Dennis W. Dickson, Aivi Nguyen, Ross R. Reichard, Matthew L. Senjem, Jeffrey L. Gunter, Clifford R. Jack, Paul H. Min, Manoj K. Jain, Toji Miyagawa, Leah K. Forsberg, Julie A. Fields, Rodolfo Savica, Jonathan Graff-Radford, Vijay K. Ramanan, David T. Jones, Hugo Botha, Erik K.
ImportanceAlthough 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a well-established cross-sectional biomarker of brain metabolism in dementia with Lewy bodies (DLB), the longitudinal change in FDG-PET has not been characterized.ObjectiveTo investigate longitudinal FDG-PET in prodromal DLB and DLB, including a subsample with autopsy data, and report estimated sample sizes for a hypothetical
-
Acute Ischemic Stroke Care Quality Improvement JAMA Neurol. (IF 20.4) Pub Date : 2025-01-13 Jinyi Zhu, Kun-Woo Rafael Kim, Hanxuan Yu, Ajay Gupta, Alvin I. Mushlin, Hooman Kamel, Ankur Pandya
This economic evaluation analyzes retrospective and prospective data in 9 quality measures to determine their value in improving care for patients who have had a stroke.
-
An Acetylcholine M1 Receptor–Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment JAMA Neurol. (IF 20.4) Pub Date : 2025-01-06 Niraj M. Shanbhag, Jaya L. Padmanabhan, Zheng Zhang, Brian T. Harel, Hongxia Jia, Tairmae Kangarloo, Wei Yin, Ariel V. Dowling, Antonio Laurenza, Polyna Khudyakov, Kevin Galinsky, Robert D. Latzman, Tanya Simuni, Daniel Weintraub, Fay B. Horak, Cindy Lustig, Paul Maruff, Arthur A. Simen
ImportanceFall risk and cognitive impairment are prevalent and burdensome in Parkinson disease (PD), requiring efficacious, well-tolerated treatment.ObjectiveTo evaluate the safety and efficacy of TAK-071, a muscarinic acetylcholine M1 positive allosteric modulator, in participants with PD, increased fall risk, and cognitive impairment.Design, Setting, and ParticipantsThis phase 2 randomized double-blind
-
Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine JAMA Neurol. (IF 20.4) Pub Date : 2025-01-06 Seonkyeong Yang, Yulia Orlova, Haesuk Park, Steven M. Smith, Yi Guo, Benjamin A. Chapin, Debbie L. Wilson, Wei-Hsuan Lo-Ciganic
ImportanceMonoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP mAbs) offer effective migraine-specific preventive treatment. However, concerns exist about their potential cardiovascular risks due to CGRP blockade.ObjectiveTo compare the incidence of cardiovascular disease (CVD) between Medicare beneficiaries with migraine who initiated anti-CGRP-mAbs
-
Intracranial Metastatic Tumor Hemorrhage During MRI Scanning JAMA Neurol. (IF 20.4) Pub Date : 2025-01-06 Wei Rao, Jin-long Mao, Wei-dong Cao
This case report describes the presentation and progression of hyperacute active hemorrhage related to an intracranial metastatic tumor as captured by magnetic resonance imaging (MRI).
-
Mood Alterations in the Prodromal Phase of Sporadic Creutzfeldt-Jakob Disease JAMA Neurol. (IF 20.4) Pub Date : 2024-12-30 Raphael Wurm, Sigrid Klotz, Astrid Erber, Felix Gruber, Stefan Leitner, Berthold Reichardt, Elisabeth Stögmann, Eva Schernhammer, Ellen Gelpi, Hakan Cetin
ImportanceSporadic Creutzfeldt-Jakob disease (sCJD) is a rare, rapidly progressive and fatal neurodegenerative disease. Definite sCJD diagnosis can only be made post mortem, and little is known about the prodromal phase of the disease.ObjectiveTo compare drug prescription patterns before the clinical onset of sCJD between patients and matched controls for exploration of potential risk factors and to
-
Gestational Hypertension, Preeclampsia, and Eclampsia and Future Neurological Disorders JAMA Neurol. (IF 20.4) Pub Date : 2024-12-23 Therese Friis, Lina Bergman, Susanne Hesselman, Linda Lindström, Katja Junus, Catherine Cluver, Carlos Escudero, Anna-Karin Wikström
ImportanceGestational hypertension, preeclampsia, and eclampsia are established risk factors for stroke and dementia later in life. Whether these pregnancy complications are associated with an increased risk of new-onset neurological disorders within months to years after giving birth is not known.ObjectiveTo explore whether gestational hypertension, preeclampsia, and eclampsia are associated with
-
Improved Measurement of Treatment Effect in Multiple Sclerosis Clinical Trials JAMA Neurol. (IF 20.4) Pub Date : 2024-12-23 Alessio Signori, Francesca Bovis, Maurizio Fedriga, Noemi Montobbio, Marta Ponzano, Irene Schiavetti, Maria Pia Sormani
This decision analytical applies restricted mean survival time as a measure of treatment effect in 2 randomized clinical trials assessing disease-modifying treatments vs placebo in patients with progressive multiple sclerosis.
-
Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG–Positive Neuromyelitis Optica Spectrum Disorder JAMA Neurol. (IF 20.4) Pub Date : 2024-12-23 Su-Hyun Kim, Ana Beatriz Ayroza Galvão Ribeiro Gomes, Patrick Schindler, Jae-Won Hyun, Ki Hoon Kim, Dong-Eun Lee, Vinicius Andreoli Schoeps, Aline de Moura Brasil Matos, Natalia Trombini Mendes, Samira Luisa Dos Apóstolos-Pereira, Dagoberto Callegaro, Jasmine Lerner, Pascal Benkert, Jens Kuhle, Klemens Ruprecht, Friedemann Paul, Anne-Katrin Pröbstel, Ho Jin Kim
ImportanceThe temporal dynamics of serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) as biomarkers of disease activity for neuromyelitis optica spectrum disorder (NMOSD) remain underexplored.ObjectiveTo determine optimal timing for assessing sGFAP and sNfL, establish cutoff values differentiating between attacks and remissions in NMOSD, and evaluate these findings
-
Spinal Cerebrospinal Fluid Leak Mimicking a Cerebellopontine Angle Tumor. JAMA Neurol. (IF 20.4) Pub Date : 2025-02-01 Wouter I Schievink,Ferdinand K Hui
-
Quality Improvement Intervention for Reducing Acute Treatment Times in Ischemic Stroke: A Cluster Randomized Clinical Trial. JAMA Neurol. (IF 20.4) Pub Date : 2025-02-01 Daniël Hansen,Sanne J den Hartog,Nikki van Leeuwen,Jelis Boiten,Wouter Dinkelaar,Pieter J van Doormaal,Frank Eijkenaar,Bart J Emmer,Adriaan C G M van Es,H Zwenneke Flach,Rob Gons,M Heleen den Hertog,Farshad Imani,Paula M Janssen,Hans Kortman,Nyika D Kruyt,Laurien S Kuhrij,Christiaan van der Leij,T H Rob Lo,Aad van der Lugt,Geert Lycklama À Nijeholt,Jasper M M Martens,Paul J Nederkoorn,Jurgen Piet,Michel
Importance Efficient care processes are crucial to minimize treatment delays and improve outcome after endovascular thrombectomy (EVT) in patients with ischemic stroke. A potential means to improve care processes is performance feedback. Objective To evaluate the effect of performance feedback to hospitals on treatment times for EVT. Design, Setting, and Participants This cluster randomized clinical
-
Neurological Pupil Index and Intracranial Hypertension in Patients With Acute Brain Injury: A Secondary Analysis of the ORANGE Study. JAMA Neurol. (IF 20.4) Pub Date : 2025-02-01 Matteo Petrosino,Elisa Gouvêa Bogossian,Paola Rebora,Stefania Galimberti,Randall Chesnut,Pierre Bouzat,Mauro Oddo,Fabio Silvio Taccone,Giuseppe Citerio,
Importance Invasive intracranial pressure (ICP) is the standard of care in patients with acute brain injury (ABI) with impaired consciousness. The Neurological Pupil Index (NPi) obtained by automated pupillometry is promising for noninvasively estimating ICP. Objectives To evaluate the association between repeated NPi and invasive ICP values. Design, Setting, and Participants This study is a secondary
-
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis JAMA Neurol. (IF 20.4) Pub Date : 2024-12-09 Eline M. E. Coerver, Wing Hee Fung, Janet de Beukelaar, Willem H. Bouvy, Leo R. Canta, Oliver H. H. Gerlach, Elske Hoitsma, Erwin L. J. Hoogervorst, Brigit A. de Jong, Nynke F. Kalkers, Zoé L. E. van Kempen, Harry Lövenich, Caspar E. P. van Munster, Bob W. van Oosten, Joost Smolders, Anke Vennegoor, Esther M. P. E. Zeinstra, Mar Barrantes-Cepas, Gijs Kooij, Menno M. Schoonheim, Birgit I. Lissenberg-Witte
ImportanceIncreasing numbers of people with multiple sclerosis (MS) use disease-modifying therapy (DMT). Long-term stable disease while taking such medications provides a rationale for considering DMT discontinuation given patient burden, costs, and potential adverse effects of immunomodulating therapy.ObjectiveTo investigate whether first-line DMT can be safely discontinued in patients with long-term
-
Protecting Neural Data Privacy-First, Do No Harm. JAMA Neurol. (IF 20.4) Pub Date : 2024-12-02 Sean Pauzauskie,Jared Genser,Rafael Yuste
-
β-Blocker Use and Delayed Onset and Progression of Huntington Disease JAMA Neurol. (IF 20.4) Pub Date : 2024-12-02 Jordan L. Schultz, Amy C. Ogilvie, Lyndsay A. Harshman, Peg C. Nopoulos
ImportanceHuntington disease (HD) is characterized by motor, cognitive, and psychiatric decline. β-Blockers may play a therapeutic role by decreasing enhanced sympathetic tone in HD.ObjectiveTo evaluate the impact of β-blockers on the timing of motor diagnosis onset and progression of HD symptoms.Design, Setting, and ParticipantsThis observational, longitudinal multicenter study used the Enroll-HD
-
β-Amyloid Positron Emission Tomography Use Across Medicare Administrative Contractor Regions JAMA Neurol. (IF 20.4) Pub Date : 2024-12-02 Zachary A. Marcum, Dominic Nunag, Adam P. Bress, Jeremy Pruzin
This cross-sectional study assesses variation in β-amyloid positron emission tomography (PET) use among Medicare beneficiaries with mild cognitive impairment or dementia by Medicare Administrative Contractor region.
-
Disease Severity Staging System for NOTCH3-Associated Small Vessel Disease, Including CADASIL JAMA Neurol. (IF 20.4) Pub Date : 2024-11-29 Gido Gravesteijn, Julie W. Rutten, Minne N. Cerfontaine, Remco J. Hack, Yi-Chu Liao, Amy A. Jolly, Stéphanie Guey, Shao-Lun Hsu, Jae-young Park, Yun Yuan, Anna Kopczak, Nicola Rifino, Sam J. Neilson, Anna Poggesi, Md Manjurul Islam Shourav, Satoshi Saito, Hiroyuki Ishiyama, Ana Domínguez Mayoral, Renata Nogueira, Elena Muiño, Pia Andersen, Nicola De Stefano, Gustavo Santo, Nontapat Sukhonpanich, Francesco
ImportanceTypical cysteine-altering NOTCH3 (NOTCH3cys) variants are highly prevalent (approximately 1 in 300 individuals) and are associated with a broad spectrum of small vessel disease (SVD), ranging from early-onset stroke and dementia (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy [CADASIL]) to nonpenetrance. A staging system that captures the full NOTCH3-SVD
-
Neuropsychological Outcomes in 6-Year-Old Children of Women With Epilepsy: A Prospective Nonrandomized Clinical Trial. JAMA Neurol. (IF 20.4) Pub Date : 2025-01-01 Kimford J Meador,Morris J Cohen,David W Loring,Abigail G Matthews,Carrie Brown,Chelsea P Robalino,Andrea Carmack,Angela K Birnbaum,Paula E Voinescu,Elizabeth E Gerard,Laura A Kalayjian,Evan R Gedzelman,Julie Hanna,Jennifer Cavitt,Maria Sam,Sean Hwang,Alison M Pack,Jacqueline A French,Jeffrey J Tsai,Cora Taylor,Page B Pennell,
Importance Antiseizure medications (ASMs) are potential teratogens commonly prescribed for multiple indications. ASM fetal exposure can impair neurodevelopment. Folate improves pregnancy outcomes, but higher doses may pose risks. Objectives To compare the outcomes of 6-year-old children of women with epilepsy (WWE) vs those of healthy women (HW), and assess the association of outcomes to third-trimester
-
Equipping AI for Unbiased and Inclusive Neurology JAMA Neurol. (IF 20.4) Pub Date : 2024-11-25 Nina F. Schor
This Viewpoint advocates for inclusive artificial intelligence (AI) training and iterative testing and cautions against the uncritical adoption of AI engines that are trained on median patient groups and exclude the outlier groups that neurology regularly treats.
-
Vertebral Web and Embolic Stroke JAMA Neurol. (IF 20.4) Pub Date : 2024-11-25 Kiran Waqar, Praveen Kesav, Seby John
This case report describes a female individual in her 30s with headache and vertigo; examination revealed acute embolic infarcts and a lesion on the vertebral artery.
-
Psychiatric Comorbidities in Persons With Epilepsy Compared With Persons Without Epilepsy JAMA Neurol. (IF 20.4) Pub Date : 2024-11-25 Churl-Su Kwon, Ali Rafati, Ruth Ottman, Jakob Christensen, Andres M. Kanner, Nathalie Jetté, Charles R. Newton
ImportanceSeveral psychiatric disorders have been found to occur more frequently in persons with epilepsy (PWE) than in persons without epilepsy.ObjectiveTo summarize the prevalence of 20 psychiatric disorders in PWE compared with persons without epilepsy.Data SourcesThe search included records from inception to February 2024 in Ovid, MEDLINE, Embase, and PsycINFO.Study SelectionPublished epidemiological
-
Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology JAMA Neurol. (IF 20.4) Pub Date : 2024-11-25 Fatme Seval Ismail, Marco Gallus, Sven G. Meuth, Hideho Okada, Hans-Peter Hartung, Nico Melzer
ImportanceAdvancements in molecular engineering have facilitated the creation of engineered T cells that express synthetic receptors, termed chimeric antigen receptors (CARs). This is promising not only in cancer treatment but also in addressing a spectrum of other conditions. This review provides a comprehensive overview of the current approaches and future potential of CAR T-cell therapy in the field
-
Wildfire Smoke Exposure and Incident Dementia JAMA Neurol. (IF 20.4) Pub Date : 2024-11-25 Holly Elser, Timothy B. Frankland, Chen Chen, Sara Y. Tartof, Elizabeth Rose Mayeda, Gina S. Lee, Alexander J. Northrop, Jacqueline M. Torres, Tarik Benmarhnia, Joan A. Casey
ImportanceLong-term exposure to total fine particulate matter (PM2.5) is a recognized dementia risk factor, but less is known about wildfire-generated PM2.5, an increasingly common PM2.5 source.ObjectiveTo assess the association between long-term wildfire and nonwildfire PM2.5 exposure and risk of incident dementia.Design, Setting, and ParticipantsThis open cohort study was conducted using January
-
AI Devices in Neurology-Moving From Diagnosis to Prognosis. JAMA Neurol. (IF 20.4) Pub Date : 2025-02-01 James M Hillis,Edward R Scheffer Cliff,Kerstin N Vokinger
-
Trends in Gender, Racial, and Ethnic Representation Among US Neurology Faculty. JAMA Neurol. (IF 20.4) Pub Date : 2025-01-01 Chia-Chen Tsai,Chen Hu,Jeffrey Ding,Esther Bui,Aleksandra Pikula,Thalia S Field,Sabeen Tiwana,Javed Siddiqi,Faisal Khosa
-
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease JAMA Neurol. (IF 20.4) Pub Date : 2024-11-18 Stephen Salloway, Jakub Wojtowicz, Nicola Voyle, Christopher A. Lane, Gregory Klein, Marco Lyons, Simona Rossomanno, Francesca Mazzo, Szofia Bullain, Frederik Barkhof, Tobias Bittner, Andres Schneider, Michael Grundman, Roxana Aldea, Mercè Boada, Janice Smith, Rachelle Doody
ImportanceData from 2 phase 3 studies of gantenerumab, GRADUATE I/II, and their open-label extensions represent a resource to further characterize amyloid-related imaging abnormalities (ARIA), including long-term sequelae.ObjectivesTo describe the characteristics of ARIA and risk factors and clinical consequences of ARIA-edema (ARIA-E).Design, Setting, and ParticipantsSecondary data collection from
-
Clinical Presentation, Investigation Findings, and Outcomes of IgG4-Related Pachymeningitis JAMA Neurol. (IF 20.4) Pub Date : 2024-11-18 Sara Terrim, João Vitor Mahler, Flávio Vieira Marques Filho, Leandro Tavares Lucato, Henrique Mayrink Giardini, Tarso Adoni, Guilherme Diogo Silva
ImportanceImmunoglobulin G4 (IgG4)–related disease is an increasingly recognized fibroinflammatory condition that can involve multiple organs, including the pachymeninges. The understanding of IgG4-related pachymeningitis (IgG4-RP) remains limited because of its rarity and the predominance of knowledge derived from case reports and case series.ObjectiveTo systematically review and synthesize the clinical
-
Gantenerumab in Dominantly Inherited Alzheimer Disease. JAMA Neurol. (IF 20.4) Pub Date : 2025-01-01 Nunzio Pomara,Bruno Pietro Imbimbo
-
Gantenerumab in Dominantly Inherited Alzheimer Disease-Reply. JAMA Neurol. (IF 20.4) Pub Date : 2025-01-01 Olivia Wagemann,Eric McDade,Randall J Bateman
-
Frailty Trajectories Preceding Dementia in the US and UK JAMA Neurol. (IF 20.4) Pub Date : 2024-11-11 David D. Ward, Jonny P. Flint, Thomas J. Littlejohns, Isabelle F. Foote, Marco Canevelli, Lindsay M. K. Wallace, Emily H. Gordon, David J. Llewellyn, Janice M. Ranson, Ruth E. Hubbard, Kenneth Rockwood, Erwin Stolz
ImportanceAn accessible marker of both biological age and dementia risk is crucial to advancing dementia prevention and treatment strategies. Although frailty is a candidate for that role, the nature of the relationship between frailty and dementia is not well understood.ObjectiveTo clarify the temporal relationship between frailty and incident dementia by investigating frailty trajectories in the
-
Epileptiform Electrographic Patterns After Cardiac Arrest JAMA Neurol. (IF 20.4) Pub Date : 2024-11-11 Andrea O. Rossetti, Sarah Benghanem
This Viewpoint challenges conventional clinical practice that eschews pharmacological intervention for comatose patients with epileptiform abnormalities after cardiac arrest using evidence from the Treatment of Electroencephalographic Status Epilepticus after Cardiopulmonary Resuscitation (TELSTAR) trial.
-
Immediate or Delayed Statin in Acute Atherosclerotic Ischemia. JAMA Neurol. (IF 20.4) Pub Date : 2025-01-01 Anastasios Kollias,Konstantinos G Kyriakoulis,Kyriakos Dimitriadis
-
Immediate or Delayed Statin in Acute Atherosclerotic Ischemia-Reply. JAMA Neurol. (IF 20.4) Pub Date : 2025-01-01 Ying Gao,Yuesong Pan,Yilong Wang
-
Deferiprone in Alzheimer Disease JAMA Neurol. (IF 20.4) Pub Date : 2024-11-04 Scott Ayton, David Barton, Bruce Brew, Amy Brodtmann, Roger Clarnette, Patricia Desmond, David Devos, Kathryn A. Ellis, Amir Fazlollahi, Caroline Fradette, Anita M. Y. Goh, Pawel Kalinowski, Christopher Kyndt, Rosalyn Lai, Yen Ying Lim, Paul Maruff, Terence J. O’Brien, Christopher Rowe, Olivier Salvado, Peter W. Schofield, Michael Spino, Fernando Tricta, Aaron Wagen, Robert Williams, Michael Woodward
ImportanceInterventions that substantially slow neurodegeneration are needed to address the growing burden of Alzheimer disease (AD) to societies worldwide. Elevated brain iron observed in AD has been associated with accelerated cognitive decline and may be a tractable drug target.ObjectiveTo investigate whether the brain-permeable iron chelator deferiprone slows cognitive decline in people with AD
-
Remembering the Physician’s Humanity—Physicians Are Humans Too JAMA Neurol. (IF 20.4) Pub Date : 2024-11-04 Noriko Anderson
This essay describes the microaggressions and burnout faced by physicians and the importance of boundaries to preserve physicians’ humanity and well-being.
-
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation JAMA Neurol. (IF 20.4) Pub Date : 2024-11-01 Bruno Dubois, Nicolas Villain, Lon Schneider, Nick Fox, Noll Campbell, Douglas Galasko, Miia Kivipelto, Frank Jessen, Bernard Hanseeuw, Mercè Boada, Frederik Barkhof, Agneta Nordberg, Lutz Froelich, Gunhild Waldemar, Kristian Steen Frederiksen, Alessandro Padovani, Vincent Planche, Christopher Rowe, Alexandre Bejanin, Agustin Ibanez, Stefano Cappa, Paulo Caramelli, Ricardo Nitrini, Ricardo Allegri
ImportanceSince 2018, a movement has emerged to define Alzheimer disease (AD) as a purely biological entity based on biomarker findings. The recent revision of the Alzheimer Association (AA) criteria for AD furthers this direction. However, concerns about a purely biological definition of AD being applied clinically, the understanding of AD by society at large, and the translation of blood-based biomarkers
-
Mobile Stroke Units-Time for Legislation and Remuneration. JAMA Neurol. (IF 20.4) Pub Date : 2024-12-01 Babak B Navi,Pooja Khatri